What question did this study set out to answer?

To evaluate clinical outcomes in patients with high-risk versus very high-risk prostate cancer treated with conformal radiation therapy and androgen deprivation therapy.

January 6, 2017Radiation OncologyOpen Access

Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

View Full Paper

Ask AI

Bookmark

Authors

ASAkram SaadLudwig Boltzmann Institute for Lung Vascular Research JGJeffrey GoldsteinUniversity of California, Los Angeles YLYaacov Richard LawrenceSheba Medical Center

Discussion

Member takes

Implication

Cohort study reveals comparable survival across risk tiers in prostate cancer treated with radiation and hormone therapy, indicating systemic treatment needs improvement.

Key Points

To evaluate clinical outcomes in patients with high-risk versus very high-risk prostate cancer treated with conformal radiation therapy and androgen deprivation therapy.
Analyzed 203 patients with high-risk prostate cancer treated between 11/2001 and 3/2012 with prostate CRT (78–82 Gy), pelvic nodal CRT (46–50 Gy), and ADT (6 months to 2 years) over a median follow-up of 50 months (range 12–142 months).
Stratified patients into four high-risk (HR) and very high-risk (VHR) cohorts based on 2014 and revised 2015 NCCN guidelines, evaluating biochemical failure by Phoenix criteria.
Assessed outcomes using Kaplan-Meier survival curves, log-rank tests, and univariate and multivariate Cox proportional hazards regression analyses.
Treatment failure occurred in 30 of 203 patients (15%) at a median of 30 months (range 4–76 months), with an overall 4-year biochemical disease-free survival (b-DFS) of 87% (95% CI: 82–92%).
Four-year b-DFS, prostate cancer-specific survival, and overall survival rates were comparable across NCCN risk subgroups, though distant metastasis-free survival (DMFS) was worse for VHR subgroups on univariate analysis (p = 0.03 and p = 0.01).
On multivariate analysis, only baseline PSA ≥ 40 ng/ml independently predicted poor 4-year b-DFS (HR: 3.75, p < 0.005) and DMFS (HR: 3.25, p < 0.005).

Cite This Study

Saad et al. (2017) studied this question.

synapsesocial.com/papers/6a7b8d3d351d91d38cc62403 https://doi.org/10.1186/s13014-016-0743-2

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals comparable survival across risk tiers in prostate cancer treated with radiation and hormone therapy, indicating systemic treatment needs improvement.

Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

Discussion

Member takes

Implication

Key Points

Cite This Study

Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider